Oxford, UK - 10 January 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announced that the Phase III TRIST trial of its novel cancer immunotherapy, TroVax, in patients with renal cancer, has been adopted by the UK National Cancer Research Network (NCRN).
